Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, Huitema ADR.

Clin Genitourin Cancer. 2018 Dec 19. pii: S1558-7673(18)30785-7. doi: 10.1016/j.clgc.2018.12.004. [Epub ahead of print] No abstract available.

PMID:
30626533
2.

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

Singh AA, Schuurman K, Nevedomskaya E, Stelloo S, Linder S, Droog M, Kim Y, Sanders J, van der Poel H, Bergman AM, Wessels LF, Zwart W.

Life Sci Alliance. 2018 Dec 28;2(1):e201800115. doi: 10.26508/lsa.201800115. eCollection 2019 Feb.

3.

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Cioni B, Jordanova ES, Hooijberg E, van der Linden R, de Menezes RX, Tan K, Willems S, Elbers JBW, Broeks A, Bergman AM, Zuur CL, de Boer JP.

Head Neck. 2018 Dec 14. doi: 10.1002/hed.25442. [Epub ahead of print]

PMID:
30549362
4.

Integrative epigenetic taxonomy of primary prostate cancer.

Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, Krijgsman O, Peeper DS, Chang SL, Feng FY, Wessels LFA, Henrique R, Jerónimo C, Bergman AM, Zwart W.

Nat Commun. 2018 Nov 21;9(1):4900. doi: 10.1038/s41467-018-07270-2.

5.

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Linder S, van der Poel HG, Bergman AM, Zwart W, Prekovic S.

Endocr Relat Cancer. 2018 Oct 31;26(1):R31-R52. doi: 10.1530/ERC-18-0289.

6.

Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.

Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, van der Heijden MS, van der Hulst JB, Sanders J, Broeks A, Kerst JM, van der Noort V, Horenblas S, Bergman AM.

J Urol. 2018 Oct 12. pii: S0022-5347(18)43985-7. doi: 10.1016/j.juro.2018.10.007. [Epub ahead of print]

PMID:
30321552
7.

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH.

Prostate Cancer Prostatic Dis. 2018 Oct 2. doi: 10.1038/s41391-018-0096-z. [Epub ahead of print]

PMID:
30279580
8.

Effects of 10 MV and Flattening-Filter-Free Beams on Peripheral Dose in a Cohort of Pediatric Patients.

Ben Bouchta Y, Goddard K, Petric MP, Bergman AM.

Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33459-X. doi: 10.1016/j.ijrobp.2018.07.2002. [Epub ahead of print]

PMID:
30071294
9.

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, Wessels LFA, Zwart W, Bergman AM.

Mol Oncol. 2018 Aug;12(8):1308-1323. doi: 10.1002/1878-0261.12327. Epub 2018 Jul 10.

10.

Androgen receptor moonlighting in the prostate cancer microenvironment.

Cioni B, Zwart W, Bergman AM.

Endocr Relat Cancer. 2018 Jun;25(6):R331-R349. doi: 10.1530/ERC-18-0042. Epub 2018 Apr 4. Review.

PMID:
29618577
11.

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

Melis MHM, Nevedomskaya E, van Burgsteden J, Cioni B, van Zeeburg HJT, Song JY, Zevenhoven J, Hawinkels LJAC, de Visser KE, Bergman AM.

Oncotarget. 2017 Sep 28;8(55):93867-93877. doi: 10.18632/oncotarget.21305. eCollection 2017 Nov 7.

12.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020. [Epub ahead of print]

13.

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Stelloo S, Nevedomskaya E, Kim Y, Hoekman L, Bleijerveld OB, Mirza T, Wessels LFA, van Weerden WM, Altelaar AFM, Bergman AM, Zwart W.

Oncogene. 2018 Jan 18;37(3):313-322. doi: 10.1038/onc.2017.330. Epub 2017 Sep 18.

PMID:
28925401
14.

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS.

Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8.

PMID:
28283282
15.

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.

Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group.

Neoplasia. 2017 Feb;19(2):93-99. doi: 10.1016/j.neo.2016.08.010. Epub 2017 Jan 12.

16.

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, Bergman AM, Beeker A, van Halteren H, Ten Tije AJ, Zuetenhorst H, van der Meer N, Chitu D, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Clin Cancer Res. 2017 Apr 1;23(7):1679-1683. doi: 10.1158/1078-0432.CCR-16-2110. Epub 2016 Oct 4.

17.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS).

Oncology. 2016;91(5):267-273. Epub 2016 Aug 20.

PMID:
27544669
18.

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

Van der Roest RC, van Houdt PJ, Heijmink SW, de Jong J, Bergman AM, Zwart W, van der Heide UA, van der Poel HG.

Urol Case Rep. 2016 May 26;7:67-9. doi: 10.1016/j.eucr.2016.04.010. eCollection 2016 Jul.

19.

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, Jenster G, Bergman AM, Zwart W.

Oncotarget. 2016 May 31;7(22):32916-24. doi: 10.18632/oncotarget.8767.

20.

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

Nevedomskaya E, Stelloo S, van der Poel HG, de Jong J, Wessels LF, Bergman AM, Zwart W.

Genom Data. 2015 Dec 28;7:124-6. doi: 10.1016/j.gdata.2015.12.020. eCollection 2016 Mar.

21.

Nocturia in women.

Kurtzman JT, Bergman AM, Weiss JP.

Curr Opin Urol. 2016 Jul;26(4):315-20. doi: 10.1097/MOU.0000000000000287. Review.

PMID:
26967265
22.

Androgen receptor profiling predicts prostate cancer outcome.

Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM, Zwart W.

EMBO Mol Med. 2015 Nov;7(11):1450-64. doi: 10.15252/emmm.201505424.

23.

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup.

Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22.

PMID:
26390914
24.

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS).

Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13.

PMID:
26278646
25.

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW.

World J Urol. 2016 Feb;34(2):157-62. doi: 10.1007/s00345-015-1636-y. Epub 2015 Jul 17.

PMID:
26184106
26.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.

27.

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.

Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S.

Clin Genitourin Cancer. 2015 Feb;13(1):44-9. doi: 10.1016/j.clgc.2014.06.005. Epub 2014 Jun 8.

PMID:
25009098
28.

Monte Carlo modeling of HD120 multileaf collimator on Varian TrueBeam linear accelerator for verification of 6X and 6X FFF VMAT SABR treatment plans.

Bergman AM, Gete E, Duzenli C, Teke T.

J Appl Clin Med Phys. 2014 May 8;15(3):4686. doi: 10.1120/jacmp.v15i3.4686.

29.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators.

Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.

30.

Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.

Foth M, Ahmad I, van Rhijn BW, van der Kwast T, Bergman AM, King L, Ridgway R, Leung HY, Fraser S, Sansom OJ, Iwata T.

J Pathol. 2014 Jun;233(2):148-58. doi: 10.1002/path.4334. Epub 2014 Mar 31.

31.

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.

Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30.

32.

Outcomes with delayed dorsal vein complex ligation during robotic assisted laparoscopic prostatectomy.

Woldu SL, Patel T, Shapiro EY, Bergman AM, Badani KK.

Can J Urol. 2013 Dec;20(6):7079-83.

PMID:
24331354
33.

Induction chemotherapy followed by surgery in node positive bladder cancer.

Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, Kerst JM, Bergman AM, Fioole-Bruining A, van Werkhoven E, Horenblas S.

Urology. 2014 Jan;83(1):134-9. doi: 10.1016/j.urology.2013.08.082. Epub 2013 Nov 15.

PMID:
24246329
34.

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW.

BJU Int. 2014 Jul;114(1):67-74. doi: 10.1111/bju.12447. Epub 2014 Jan 17.

35.

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

Wissing MD, van Oort IM, Gerritsen WR, van den Eertwegh AJ, Coenen JL, Bergman AM, Gelderblom H.

Clin Genitourin Cancer. 2013 Sep;11(3):238-250.e1. doi: 10.1016/j.clgc.2013.04.004. Epub 2013 May 6.

PMID:
23659772
36.

A Monte Carlo approach to validation of FFF VMAT treatment plans for the TrueBeam linac.

Gete E, Duzenli C, Milette MP, Mestrovic A, Hyde D, Bergman AM, Teke T.

Med Phys. 2013 Feb;40(2):021707. doi: 10.1118/1.4773883.

PMID:
23387730
37.

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.

Meijer RP, Nieuwenhuijzen JA, Meinhardt W, Bex A, van der Poel HG, van Rhijn BW, Kerst JM, Bergman AM, van Werkhoven E, Horenblas S.

Eur J Surg Oncol. 2013 Apr;39(4):365-71. doi: 10.1016/j.ejso.2013.01.003. Epub 2013 Jan 31.

PMID:
23375648
38.

FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.

Mertens LS, Fioole-Bruining A, van Rhijn BW, Kerst JM, Bergman AM, Vogel WV, Vegt E, Horenblas S.

J Urol. 2013 May;189(5):1687-91. doi: 10.1016/j.juro.2012.11.009. Epub 2012 Nov 6.

PMID:
23142689
39.

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S.

J Urol. 2012 Oct;188(4):1108-13. doi: 10.1016/j.juro.2012.06.018. Epub 2012 Aug 15.

PMID:
22901581
40.

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.

Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R.

BMC Cancer. 2010 Oct 11;10:545. doi: 10.1186/1471-2407-10-545.

41.

A novel solution to reduce the complications of distal shunt catheter displacement associated with obesity.

Morrison JF, Sung KE, Bergman AM, Rosenblatt MS, Arle JE.

J Neurosurg. 2010 Dec;113(6):1314-6. doi: 10.3171/2010.6.JNS10300. Epub 2010 Jul 9.

PMID:
20617878
42.

Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.

Sigmond J, Bergman AM, Leon LG, Loves WJ, Hoebe EK, Peters GJ.

Anticancer Drugs. 2010 Jul;21(6):591-9. doi: 10.1097/CAD.0b013e32833a3543.

PMID:
20436341
43.

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

Graafland NM, Valdés Olmos RA, Teertstra HJ, Kerst JM, Bergman AM, Horenblas S.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1474-80. doi: 10.1007/s00259-010-1434-0. Epub 2010 Mar 27.

PMID:
20349185
44.

Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.

van der Poel HG, Zevenhoven J, Bergman AM.

Urol Int. 2010;84(2):212-20. doi: 10.1159/000277601. Epub 2010 Mar 4.

PMID:
20215828
45.

Development and operation of research-scale III-V nanowire growth reactors.

Schroer MD, Xu SY, Bergman AM, Petta JR.

Rev Sci Instrum. 2010 Feb;81(2):023903. doi: 10.1063/1.3310111.

PMID:
20192505
46.

Monte Carlo based, patient-specific RapidArc QA using Linac log files.

Teke T, Bergman AM, Kwa W, Gill B, Duzenli C, Popescu IA.

Med Phys. 2010 Jan;37(1):116-23.

PMID:
20175472
47.

Monte Carlo calculation of dose distribution in early stage NSCLC patients planned for accelerated hypofractionated radiation therapy in the NCIC-BR25 protocol.

Moiseenko V, Liu M, Bergman AM, Gill B, Kristensen S, Teke T, Popescu IA.

Phys Med Biol. 2010 Feb 7;55(3):723-33. doi: 10.1088/0031-9155/55/3/012. Epub 2010 Jan 13.

PMID:
20071759
48.

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.

Invest New Drugs. 2011 Jun;29(3):456-66. doi: 10.1007/s10637-009-9377-7. Epub 2010 Jan 12.

49.

Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.

Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM, van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman AM, Giaccone G, Peters GJ.

Ann Oncol. 2009 Jan;20(1):182-7. doi: 10.1093/annonc/mdn543. Epub 2008 Aug 12.

PMID:
18701427
50.

The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.

Sigmond J, Kamphuis JA, Laan AC, Hoebe EK, Bergman AM, Peters GJ.

Biochem Pharmacol. 2007 May 15;73(10):1548-57. Epub 2007 Jan 21.

PMID:
17324380

Supplemental Content

Loading ...
Support Center